Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 12/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30475527 | 0.95 | MME (0.56) | OPRM1OPRD1MMEBACE1CTSD | |
| SCHEMBL30475525 | 0.95 | MME (0.56) | OPRM1OPRD1MMEBACE1CTSD | |
| SCHEMBL30475526 | 0.95 | MME (0.56) | OPRM1OPRD1MMEBACE1CTSD | |
| SCHEMBL18047563 | 0.92 | BACE1 (0.56) | OPRM1OPRD1MMEBACE1CTSD | |
| SCHEMBL30273399 | 0.89 | BACE1 (0.52) | BACE1CTSDBACE2 | |
| SCHEMBL30390471 | 0.89 | MME (0.58) | OPRM1OPRD1MMEBACE1CTSD | |
| SCHEMBL31343151 | 0.89 | MME (0.55) | OPRM1OPRD1MMEBACE1BACE2 | |
| SCHEMBL31215109 | 0.88 | OPRD1 (0.62) | OPRM1OPRD1MME | |
| SCHEMBL30735658 | 0.88 | OPRD1 (0.62) | OPRM1OPRD1MME | |
| SCHEMBL30799525 | 0.88 | BACE1 (0.58) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | OPRM1 3822/4885OPRD1 4036/4885MME 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.